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Resumo  
 
Cancro da bexiga é o nono tumor mais comum a nível mundial, com uma estimativa de 429 000 novos 
casos registados, em 2012, e aproximadamente 165 000 mortes registadas, nesse mesmo ano, em todo o 
mundo. Os parâmetros clínicos e patológicos usados para avaliar o estádio do cancro da bexiga têm elevadas 
limitações e até à data ainda não existe nenhum biomarcador que preveja o comportamento tumoral em cada 
paciente. Por este motivo, é essencial a identificação de novos biomarcadores que estejam envolvidos na 
progressão tumoral e que permitam reconhecer diferentes tumores de acordo com a sua capacidade 
progressiva e invasiva. A classificação dos diferentes subtipos de tumor da bexiga permitirá desenvolver 
um tratamento especializado e individualizado, o que possibilitará uma melhoria da qualidade de vida e da 
taxa de sobrevivência destes doentes. 
O gene TP63 pertence à família do supressor de tumor TP53. No entanto ao contrário do TP53, que 
se encontra mutado em grande parte dos tumores, o gene TP63 raramente está na sua forma mutada. Ainda 
assim, a expressão do gene TP63 está alterada em alguns tumores. A isoforma do gene TP63, designada por 
∆Np63, tem sido estudada como um possível biomarcador na área da oncologia, pois existem evidências 
que a relacionam com a progressão do tumor da bexiga não invasivo da camada muscular (NMIBC) para 
um tumor invasivo da camada muscular (MIBC). Estudos sugerem que esta isoforma inibe a senescência e 
a apoptose celular assim como promove a tumorogénese, proliferação e sobrevivência celular, exibindo 
características oncogénicas. No tecido normal da bexiga, o ∆Np63 tem uma alta/elevada expressão enquanto 
que no tecido tumoral de bexiga esta isoforma encontra-se subregulada.  
Este projeto foi iniciado em Mount Sinai, Nova Iorque, pela orientadora deste trabalho, Dr.ª Mireia 
Castillo, onde, após inativar o gene ∆Np63 das linhas celulares de NMIBC (RT112 e BFTC), observou que 
estas células apresentavam maior taxa de proliferação in vitro e in vivo, maior taxa de invasão in vitro e 
maior incidência de tumores primários e formação de metástases in vivo. Deste modo, foi necessário validar 
os resultados na Fundação Champalimaud e verificou-se, através do modelo ortotópico in vivo, que as 
células clones (BFTC_C e RT112_C) apresentaram maior agressividade tumoral e maior formação de 
metástases, assim confirmando o que tinha sido observado anteriormente. Através da análise da expressão 
génica, observou-se ainda que ambas as linhas celulares apresentavam nove e quatro genes, respetivamente 
sobrerregulados e subregulados, concomitantemente nas duas linhas celulares, respetivamente. 
Desta forma, o segundo objetivo deste projeto consistiu em descobrir quais dos genes selecionados 
na análise de expressão génica seriam mais relevantes na progressão tumoral. No entanto, apenas quatro dos 
nove sobrerregulados (AGR2, HOXC6, HRK e S100A4) e dois dos quatro genes subregulados (SCML1 e 
SPOCK1) foram estudados, com base no seu relacionamento com o desenvolvimento tumoral referido na 
literatura e também por existirem bons anticorpos e primers específicos. Deste modo, extraiu-se RNA das 
quatro linhas celulares (RT112_L_C, RT112_L_P, BFTC_L_C e BFTC_L_P) para realizar ensaios 
quantitativos de reação em cadeia de polimerase em tempo real (qRT-PCR) de forma a validar os resultados 
obtidos pela análise da expressão génica. A partir das mesmas linhas celulares foi extraída proteína para 
realizar ensaios de western blot (WB) e ensaios de imunofluorescência (IF), estes últimos foram realizados 
em células fixadas. Estas técnicas permitiram quantificar os níveis de proteína em cada linha celular 
(BFTC_P, BFTC_C, RT112_P e RT112_C). Após comparar os níveis de RNA mensageiro (mRNA) e de 
proteína, AGR2 foi o gene eleito como um dos favoritos a ter um papel essencial na progressão do tumor da 
bexiga. AGR2 tem maior expressão de mRNA nas células clones (∆Np63-) comparativamente com as 
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parentais (∆Np63+) (observado apenas na linha celular designada BFTC). Relativamente à síntese de 
proteína, os resultados do WB sugerem que AGR2 é produzida em maior quantidade nas células clones 
(∆Np63-) do que nas parentais (∆Np63+) (em ambas as linhas celulares) e através de IF observa-se o mesmo 
resultado na linha celular BFTC. Outros estudos sugerem que o gene AGR2 tem funções extracelulares que 
aumentam a agressividade de diferentes tumores, como por exemplo o cancro do pulmão, da mama e da 
próstata. Além disso, expressão de mRNA de AGR2 é elevada no carcinoma de células de transição da 
bexiga, adenocarcinoma da próstata e do pulmão.  
A desativação do gene foi feita em cinco conjuntos de células de cada linha celular de NMIBC, onde 
já tinha sido inativado a isoforma ∆Np63 do gene TP63, formando cinco clones de cada linha celular, 
designados por BFTC_A1, BFTC_A2, BFTC_A3, BFTC_A4 e BFTC_A5, assim como para a linha celular 
RT112. Após silenciamento do gene AGR2 por shRNA nas células BFTC_C e RT112_C, estudaram-se os 
níveis de mRNA por qRT-PCR, e de proteína através das técnicas de WB e IF para determinar a eficiência 
da eliminação do mesmo. Estes estudos só foram realizados para a linha celular BFTC. O clone BFTC_A5 
mostrou ser o que apresentava menor nível de mRNA e respetiva proteína AGR2, por isso esta linha celular 
foi utilizada para estudos funcionais, como ensaios de ciclo celular, ensaios de proliferação e ensaios de 
invasão celular. Os estudos funcionais foram essenciais para observar se o gene AGR2 está envolvido na 
progressão celular. Ensaios de ciclo celular revelaram que as células tumorais designadas BFTC_A5 
(∆Np63- AGR2-) apresentaram menor divisão celular comparativamente às células tumorais BFTC_C 
(∆Np63- AGR2+) e BFTC_P (∆Np63+ AGR2+), in vitro. As células tumorais BFTC_A5 (∆Np63- AGR2-) 
revelaram ainda menor capacidade de proliferação e de invasão celular, in vitro. 
Estes estudos sugerem que o gene AGR2 pode estar envolvido na progressão do tumor da bexiga não 
invasivo da camada muscular (NMIBC) para invasivo da camada muscular (MIBC). As células tumorais 
que sintetizam em simultâneo a isoforma ∆Np63 e o gene AGR2 (BFTC_P) revelaram não ter capacidades 
tão proliferativas e tão invasoras como as células tumorais que apenas sintetizam AGR2 (BFTC_C). No 
entanto quando o gene AGR2 é desligado, estas células tumorais voltam a perder a sua capacidade invasora 
e proliferativa, sugerindo assim que o gene AGR2 é essencial para a proliferação e invasão tumoral.  
Este trabalho é o primeiro que estuda a interação entre o produto do gene AGR2 e a isoforma ∆Np63 
do gene TP63 na progressão do tumor da bexiga não invasivo da camada muscular. No entanto mais estudos 
serão necessários para confirmar esta hipótese, nomeadamente estudos com o modelo ortotópico in vivo e 
também a análise de imunofluorescência de microarrays de tumores (TMA) que irá validar os resultados in 
vitro, assim como correlacionar a expressão do AGR2 com as características do doente (prognóstico, 
presença de metástases, risco de progressão, entre outros). Além disso, é também necessário realizar os 
mesmos ensaios, descritos neste trabalho, para a linha celular RT112. 
Neste trabalho, AGR2 é descrito como um potencial fator de progressão de NMIBC para MIBC. O 
gene AGR2 é importante para o desenvolvimento do tumor e poderá ser um biomarcador com a capacidade 
de distinguir tumores que devem sofrer um tratamento mais ou menos invasivo. Como por exemplo, 
pacientes com tumores de elevado risco de progressão poderão beneficiar de uma cistectomia, enquanto que 
pacientes com tumores de baixo risco de progressão poderão usufruir de um tratamento menos invasivo e 
de vigilância médica com alguma regularidade. 
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A existência de um anticorpo contra a proteína AGR2 pode permitir o desenvolvimento de ensaios 
clínicos em doentes com NMIBC, de modo a testar a sua efetividade no controlo da progressão destes 
mesmos tumores. 
 
Palavras-chave: Cancro, Bexiga, NMIBC, ∆Np63, AGR2. 
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Abstract  
 
∆Np63, an isoform of TP63 gene, has been described as an essential marker for Non-Muscle Invasive 
Bladder Cancer (NMIBC) progression. After knocking down ∆Np63 in NMIBC cell lines, nine and four 
genes were found up-regulated and down-regulated, respectively, through gene expression analysis, in two 
different bladder tumor cell lines (RT112 and BFTC). From this set of genes, four up-regulated (AGR2, 
HOXC6, HRK and S100A4) and two down-regulated genes (SCML1 and SPOCK1) were chosen for further 
analysis due to the availability of good antibodies and primers, in order to discover which of those genes 
are more relevant to bladder cancer progression. With this purpose, total RNA was extracted from BFTC 
and RT112 cells (both parental and knock down for ∆Np63) to perform quantitative real-time polymerase 
chain reaction (qRT-PCR) and to validate the gene expression analysis. From the same cell lines, proteins 
were extracted to performed western blot (WB) analysis and immunofluorescence (IF) assays and the 
protein and RNA levels were compared. The obtained results suggest that AGR2 gene was the most related 
in bladder cancer progression. In addition, mRNA level of AGR2 was higher in knock down clones than in 
parental cells (verified only in BFTC cells) and WB results showed that AGR2 protein was also higher in 
knock down than in parental cells. Similar results were observed by IF assay in BFTC cells. Other studies 
suggested that AGR2 has extracellular functions that increase aggressiveness of different tumors. Moreover, 
AGR2 mRNA expression has been described as high in urinary bladder transitional cell carcinoma, prostate 
adenocarcinoma and lung carcinoma. To study the effects of that gene in bladder tumor progression, AGR2 
was knocked down in RT112_C and BFTC_C cells which had already been knocked down for ∆Np63 and 
mRNA and protein level studies were performed again through qRT-PCR, WB and IF techniques. After 
selection of the cell line with lower level of mRNA and protein AGR2, BFTC_A5, functional studies were 
performed, such as cell cycle, invasion and proliferation assays. Functional studies showed that BFTC_A5 
(∆Np63- AGR2-) cells displayed lower cell division, lower proliferative and invasive capacities compared 
with BFTC_C (∆Np63- AGR2+), which suggest that AGR2 may has a role in bladder tumor progression. 
 
Key words: Cancer, Bladder, NMIBC, ∆Np63, AGR2. 
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1 Introduction 
 
1.1 Bladder Cancer 
The bladder is a hollow organ in the pelvis and it is formed by a muscle wall that stretches to 
accommodate urine and coated by a mucosa named urothelium. The urothelium is a transitional epithelium, 
which has several layers and it is made up of different types of cells.  
Bladder Cancer (BC) is the ninth most common cancer with an estimated of 429 000 new cases 
occurred in 2012 and approximately 165 000 deaths per year worldwide1,2. Europe has the highest incidence 
rates of BC in the world, with an estimated of 151 200 new cases and 52 400 deaths occurred in 20122,3.   
The most common type of BC is urothelial carcinoma (UC) also named transitional cell carcinoma 
(TCC), because it develops from the transitional epithelium of the bladder4. Depending on the depth of 
invasion through the bladder wall, BC can be classified in two different groups: Non Muscle Invasive 
Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC)5. NMIBC is also known as 
superficial BC and is the most frequent group, comprising 75% of the cases at first diagnosis. NMIBC 
includes stages Tis (also called carcinoma in situ, CIS), Ta and T1, which have not grown into the muscle 
layer of the bladder wall, whereas MIBC includes stages T2 to T4 which have invaded the muscle layer of 
the bladder or further (Figure 1.1). Patients with NMIBC have higher chance of survival, around 88-98% 
Figure 1.1 Origin and evolution of urothelial carcinoma. Normal bladder is formed by three layers: mucosa layer, submucosa 
layer and muscle layer. From normal bladder to bladder cancer there are two tumor pathways with divergent genetic backgrounds. 
Urothelial carcinoma can be low or high grade, depending on the degree of differentiation. Papillary and flat pathways are two 
distinct tumor morphologies, depending on tumor growth. Bladder cancer can finally be classified as NMIBC, including stages Tis, 
Ta and T1, or as MIBC, including T2 to T4 stages, depending on invasion of the muscular layer. This figure is adapted from Mireia 
Castillo-Martin et al.19. 
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after 5 years, although also a higher chance of recurrence, around 60%, when compared to MIBC5,6. 
Depending on the differentiation degree, BC can be divided in low grade (LG) and high grade (HG), with 
LG tumors having propensity for recurrence and a good prognosis whereas high grade tumors progress 
faster and have a worse prognosis. Approximately, 20% of HG NMIBC progress to an invasive and very 
aggressive tumors7.   
Urothelial carcinoma arises through two distinct molecular pathways with specific histological 
features, referred as papillary, occurring in 80% of the cases, and non-papillary pathways, occurring in 
20%8,9 (Figure 1.1). Papillary carcinomas grow in finger-like projections from the inner surface of the 
bladder, usually without invading into deeper bladder layers, called also non-muscle invasive (NMI) 
papillary tumors. These tumors have a high tendency for recurrence but rarely invade the bladder wall or 
metastasize. On the other hand, non-papillary tumors can evolve from CIS and they can be aggressive 
enough to invade the bladder wall and to metastasize. LG papillary tumors can progress to HG NMI tumors, 
typically by the presence of CIS in the adjacent mucosa8. Likewise, T1 HG tumors (that invade the lamina 
propria but do not invade the muscular layer) are associated with high risk of progression, metastasization 
and death, depending on the depth of invasion of the lamina propria and in the presence of CIS10. CIS is a 
flat HG NMI lesion that can progress to MIBC in 35% to 55% of the cases in 5 years, representing the cause 
of death in 39% of the patients with BC11,12. Some epithelial tumors progress by successive mutations in 
crucial genes that are responsible for growth regulation, survival, apoptosis and cell-cell interactions13. 
These two distinct pathways of BC have different genetics characteristics: LG NMI papillary tumors are 
characterized by loss of heterogeneity (LOH) of chromosome 9 and by mutations in harvey rat sarcoma 
viral oncogene (H-RAS), in fibroblast growth factor receptor 3 (FGFR3) and in phosphoinosite-3-kinase 
(PI3K) genes, while CIS has structural and functional defects in the TP53, RB tumor-suppressor pathways 
and in phosphatase and tensin homolog (PTEN) gene14–18. Complete loss of TP53 gene has been shown to 
be involved in the development of CIS, and TP53 loss concomitant with loss of RB functions can induce 
tumor progression19. MIBC is characterized by extended genomic aberrations, including LOH of 
chromosome 3, 5, 6, 10, 11 and 1820–24. 
Due to the discovery of different molecular backgrounds in BC, MIBC was recently classified in 
molecular subtypes25. Luminal tumors are enriched with uroplakins, CK20 and CK18 and have upregulation 
of peroxisome proliferator – activated receptor gamma (PPARG), all characteristic of 
intermediate/superficial layers of normal urothelium. Luminal tumors express E-cadherin, HER2/3, RAB-
25 and SRC and have enrichment of FGFR3, ELF3, CDKN1A and TSC1 mutations. On the other hand, basal 
tumors are enriched with expressions of KRT5, KRT14 and CD44 and show up-regulation of TP63 target 
genes, TP53 and RB1 mutations and show overexpression of CD49, Cyclin B1 and EGFR, similar to cells 
in the basal layer of normal urothelium9,26. Luminal tumors have shown a better prognostic than basal 
cancers. 
Other histological types of cancer can develop in the bladder, including squamous cell carcinoma 
(SCC, 5 % of the tumors), adenocarcinoma (<1 %), and sarcomas (extremely rare), amongst others.  
1.2 Risk Factors 
BC is mostly caused by exposure to carcinogenic chemical agents. Tobacco, whether be active or 
passive smoking, is the leading risk factor for BC, mainly due to exposure to chemical carcinogens such as 
4-aminobiphenyl and o-toluidine. Active smokers have 4-fold higher risk of BC incidence, similar to people 
who started smoking at a younger age or that were exposed to tobacco smoke during childhood27,28. 
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Occupational exposure to aromatic amines is another risk factor, for example, exposure to 2-naphthylamine, 
4-aminobiphenyl and benzidine and exposure to 4,4’-methylenebis in the dye and rubber industries as well 
as exposure to hair dyes, house paints, fungicides, ionizing radiation, plastics and others agents can induce 
BC in 10-15 %9,29. Exposure to arsenic and chlorination by products in drinking water represents another 
group of important risk factors30. Chlorine is used to disinfect drinking water and swimming pools and it 
can dissociate itself in trihalomethanes and when it is present in drinking water can increase the risk of BC. 
The treatment by radiation of nearby cancers, such as prostate cancer, has also been reported to induce BC. 
Some other medical conditions may rise the risk of BC, such as the treatment of diabetic patients with 
pioglitazone drug for more than 2 years31. People with bladder infections or who suffer from chronic bladder 
infections have also more risk of BC. For example, bladder infection by the Schistosoma parasite can induce 
chronic irritation and inflammation in the urinary bladder, presenting higher incidence of squamous cell 
carcinoma32.  
Family history of BC is also associated with an increased risk for BC mainly resulting of the shared 
smoking habits. However, some genes have been associated with increased risk of BC such as N-
acetyltransferase 2 (NAT2) and slow acetylator and glutathione S-transferase µ (GSTM1) because their 
mutated form cannot break some toxins which will accumulate in the bladder9,33. MSH2 mutation found in 
Lynch syndrome is also associated with a 4.2-fold risk increase for BC in men before the age of 7033. 
Similarly, people with Cowden disease, caused by mutations in PTEN gene, have higher risk of developing 
BC. Despite that, BC consequent of family history is extremely rare34.  
Interestingly, bladder cancer affects men and women in different ways. While men present a 
considerable higher risk of developing UC of the bladder, women show more advanced disease stages and 
seem to experience more unfavorable outcomes35. 
 
1.3 TP63 and Bladder Cancer 
TP63, a member of the TP53 gene family, has been reported as a potential marker of bladder tumor 
progression36,37. TP63 regulates cell-cycle arrest and apoptosis and encodes two isoforms depending on 
different promoter use: transcriptionally active (TA) p63 and dominant negative (∆N) p63 (Figure 1.2) 38. 
Both TAp63 and ∆Np63 are composed by three isoforms, named α, β and ƴ depending on alternative 
splicing. 
In cancer, TP63 activity is thought to be isoform-specific, with ∆Np63 isoform apparently having an 
oncogenic role and TAp63 possessing tumor suppressor functions. The TAp63 isoform induces cell cycle 
Figure 1.2 p63: protein domain structure. Schematic diagram of p63 isoforms showing the transactivation domain (TAD), DNA 
binding domain (DBD), oligomerization domain (OD) and sterile α motif (SAM). 
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arrest and apoptosis by transactivation of TP53 whereas ∆Np63 isoform plays a role in blocking 
transactivation of both TP53 and TAp63 isoforms of TP63. Unlike TP53, mutation of the TP63 gene is very 
rare in cancer, instead, it is silenced by epigenetic factors39. ∆Np63 shows increased expression levels in 
tumor cells while TAp63 expression levels decrease40,41. Therefore, in normal tissue, the detection of ∆Np63 
expression is very low, whereas the expression of TAp63 is normal, suggesting that ∆Np63 can be an proto-
oncogene38,39,42. Even more, previous studies have shown that the same isoform can have different clinical 
implications in NMIBC and MIBC43. Due to these conflicting results, currently there is no consensus about 
TP63 being a proto-oncogene or a tumor suppressor, because the different isoforms seem to have opposite 
effects41,44,45. Gaya et al. reported that ∆Np63 expression is a marker of good prognosis in HG-NMIBC, 
since patients whose tumors express this biomarker do not suffer disease progression to MIBC, and 
subsequently, they do not die from the disease36. 
 
1.4 Treatment of Bladder Cancer 
Treatment of BC depends on the clinical stage and grade at presentation: MIBC needs to be radically 
treated either by radical cystectomy or systemic therapies or both combined. NMIBC may be removed by 
trans-urethral resection (TUR) and followed-up to avoid or early detect progression to MIBC. Half of the 
patients with NMIBC, who are treated with TUR, suffer disease recurrence, and 5-25% of these patients 
progress to MIBC after repeated recurrences46. After TUR, LG Ta tumors are treated with intravesical 
chemotherapy with Mitomycin C or bacillus Calmette-Guerin (BCG) treatment for 1 year while T1 tumors 
usually undergo a second TUR followed by BCG treatment for 1 to 3 years47,48. On the other hand, high 
grade NMIBC patients are treated with BCG treatment or intravesical chemotherapy and close follow-up49. 
T1 tumors with high-risk of progression determined by clinical and pathological parameters (including size, 
multiplicity, localization, associated CIS, prostatic urethra involvement and female gender) may be treated 
upfront with radical cystectomy to avoid early progression to MIBC, which sometimes may result in an 
overtreatment50.  
 
1.5 Biomarkers to Guide BC Clinical Management  
NMIBC and MIBC have distinct pathways in carcinogenesis as illustrated in Figure 1.1 above. One 
pathway involves mutation of FGFR3 which is thought to be involved in tumor recurrence51,52. This 
mutation is more frequent in patients with NMIBC than in patients with MIBC at the time of diagnosis but 
FGFR3 mutation has not been recognized to be a prognostic biomarker in advanced BC. In contrast, MIBC 
and CIS exhibit deletions and mutations of TP53, RB1 or PTEN. TP53 has a role in induction of apoptosis, 
inhibition of cell proliferation and arrest of the cell cycle. Nuclear accumulation of p53, which is a poor 
prognostic factor, is found in 53% of patients who underwent cystectomy in MIBC53,54. The RB1, a tumor 
suppressor gene, is a negative regulator of the cell cycle. Loss of RB1 expression is an adverse prognostic 
biomarker in MIBC53. Bladder cancer with mutation of the RB1 gene exhibit low FGFR3 levels and it is 
associated with significantly poor disease-specific survival55. Pietzak et al. identified genetic alterations 
with potential clinical implications in NMIBC56. The most frequently altered genes in NMIBC were the 
TERT promoter (73 %), FGFR3 (49 %), KDM6A (38 %), PIK3CA (26 %), STAG2 (23 %), ARID1A (21 %) 
and TP53 (21 %)56,57. 
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Several markers associated with genetic alterations have been identified both in NMIBC and MIBC. 
Unfortunately, the clinical and pathological parameters have limited prognostic ability and to date no 
biomarker has been able to predict tumor behavior in an individual patient. Therefore it is important to 
identify new biomarkers involved in bladder cancer progression that can help clinicians provide 
individualized risk-stratified decision-making to define which NMIBC patients should be treated with 
immediate radical cystectomy58.   
Functional studies by our group revealed higher proliferation rate both in vitro and in vivo as well as 
increased colony formation activity after knocking down ∆Np63 in NMIBC cells (data not published). 
Furthermore, these cells displayed superior invasion capacity in vitro, which correlated with higher local 
tumor initiation and metastatic potential in an in vivo bladder orthotopic mouse model. Gene expression 
analyses revealed that there were nine (AGR2, CAPS, CHD2, GCHFR, HOXC6, HRK, LRRC26, SORBS2 
and S100A4) and four (EPDR1, PPARG, SCML1 and SPOCK1) commonly up-regulated and down-
regulated genes, amongst the experimental cell lines.  
Bearing in mind that ∆Np63 isoform could be involved in bladder tumor progression, this work 
focused in studying the genetic modifications associated with this ∆N isoform loss concomitant with more 
aggressive tumors.  
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2 Working Hypothesis and Goals 
 
Considering the relevant role of ∆Np63 in progression of HG NMIBC to MIBC, the main goal of this 
work is to discover the genetic alterations associated with this TP63 isoform loss that confer the aggressive 
phenotype to tumor cells. The hypothesis being tested here is that, amongst the differentially regulated 
genes, AGR2 may be key in this transformation. To fulfill this final goal, the following objectives will be 
pursed, by using several in vitro and in vivo models: 
1. Validation of the results obtained by the gene expression arrays for the different genes by qRT-PCR 
and protein assays (WB and IF). 
2. Knocking-down AGR2 in NMIBC cells using shRNA technology and validation of the 
downregulation of the gene. 
3. Perform cell cycle, proliferation and invasion in vitro assays to determine the effect of AGR2 knock-
down in NMIBC cells. 
This knowledge will allow a better understanding of the mechanisms of BC progression and in the 
future, it could help determine how patients with HG NMIBC should be treated, depending on their tumor 
molecular characteristics as a complement to tumor clinico-pathological features. 
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3 Material and Methods 
 
3.1 Cell Culture 
Two different HG NMIBC commercially available cell lines, RT112 and BFTC, were used for the 
experiments. These cells came from Dr. Cordon-Cardo’s Laboratory at the Icahn School of Medicine at 
Mount Sinai (New York, USA). First, both lines were transfected with the firefly luciferase gene, and were 
named RT112_L_P and BFTC_L_P (parental). Then, clones with downregulation of ∆Np63 gene by 
shRNA technology were generated, called RT112_L_C and BFTC_L_C (Figure 3.1). These steps were 
performed previous to the start of this master project. For this project, AGR2 was knocked down by shRNA 
technology in the cells previously ∆Np63 knock down.  RT112 cells were grown and maintained in RPMI 
medium (Lonza #BE12-702F) supplemented with 10 % fetal bovine serum (FBS, Biowest #S181BH-500) 
and 1 % Penicillin/Streptomycin (P/S, Gibco #15140-122) at 37 °C in a humidified atmosphere of 5 % CO2. 
BFTC cells were grown and maintained in DMEM medium (Lonza #BE12-604F) supplemented with 10 % 
FBS and 1 % P/S at 37 °C in humidified atmosphere of 5 % CO2. 
 
 
 
 
 
 
Human cancer cell line HeLa and MCF-7 were offered by Henrique Veiga-Fernandes Laboratory, 
IMM (Lisbon, PT) and by the Cancer and Telomere’s Laboratory, Champalimaud Foundation (Lisbon, PT), 
respectively. MCF-7 cells were grown and maintained in the same conditions as BFTC cells and HeLa cells 
A 
B 
Figure 3.1 Schematic figure of the NMIBC cell lines used in this work. A: BFTC cell line (yellow cytoplasm) was transformed 
with a firefly luciferase gene that conferred bioluminescence signal to the cells (L). These cells were called BFTC_L_P (dark blue 
cytoplasm) because the only alteration that they have is the luciferase gene. BFTC_L_P cells suffered a knockdown of ∆Np63 gene 
and were called BFTC_L_C (lighter blue cytoplasm). Then, BFTC_L_C were knockdown for AGR2 gene and were called 
BFTC_L_A (grey cytoplasm). All of BFTC cell lines studied in this work have the luciferase gene (green membrane). B: RT112 
cell line (yellow cytoplasm) was transformed with a firefly luciferase gene that conferred bioluminescence signal to the cells (L). 
These cells were called RT112_L_P (red cytoplasm) because the only alteration that they have is the luciferase gene. RT112_L_P 
cells suffered a knockdown of ∆Np63 isoform and were called RT112_L_C (orange cytoplasm). Then, RT112_L_C were 
knockdown for AGR2 gene and were called RT112_L_A (grey cytoplasm). All of RT112 cell lines studied in this work have the 
luciferase gene (green membrane).  
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were grown and maintained in EMEM medium (SIGMA #M2279) supplemented with 10 % FBS, 1 % P/S, 
1 % non-essential amino acids (NEAA, Sigma-Aldrich #M7145) and 2 mM L-Glutamine (Biowest #X0551-
100) at 37 °C in a humidified atmosphere of 5 % CO2. 
 
3.2 RNA Extraction and quantitative Real Time PCR 
Total RNA was extracted from cultured cells using the RNeasy Mini Kit (Qiagen #74104) following 
manufacturer’s protocol, and concentration and quality assessment was measured using Nanodrop™ 2000 
platform. 1µg of mRNA for each cell line (BFTC_L_P, RT112_L_P, BFTC_L_C and RT112_L_C) was 
converted into cDNA using SuperScript III First-Strand Synthesis kit (Invitrogen #18080-051) according to 
manufacturer’s instructions. The concentration of SuperScript III Reverse Transcriptase used was 100 U/µL.  
Quantitative real-time PCR assay allowed to measure the mRNA level in each cell line. This 
technique with Power SYBR Green PCR Master Mix (Applied Biosystems #4367659) was performed 
according to the manufacturer’s instructions using Biorad CFX96 instrument (Bio-Rad). The sequences of 
all forward and reverse primers used to analyze the genes of interest (Invitrogen) are summarized in Table 
8.1 (supplementary data). The PCR conditions were: initial denaturation at 95 °C for 15 minutes, 40 cycles 
of denaturation at 94 °C for 30 seconds, annealing at 60 °C for 40 seconds and elongation at 72 °C for 30 
seconds, finishing at 4 °C. GAPDH gene was used as an endogenous control. Analysis was performed by 
using Bio-Rad CFX Manager software program (Bio-Rad). Relative fold change of target genes was 
calculated by2−∆∆𝐶𝑡, where (Equation 3.1): 
Equation 3.1: 
- ∆∆Ct = - [∆Ctclones(target-GAPDH) - ∆CtParental(target-GAPDH)] 
 
The normalization was defined to the relative expression detected as 1. For each reaction, melting 
curve analysis was performed to ensure presence of a single amplicon. Experiments were run in triplicates. 
 
3.3 Immunofluorescence Assay 
Immunofluorescence (IF) assay allowed quantifying and verifying the subcellular localization of the 
protein. IF staining was performed on fixed cells. First, coverslips were sterilized in 95 % of ethanol for 10 
minutes and then one coverslip was placed in a well of a 6-well plate and let dry. Meanwhile, cells were 
trypsinized and 100 000 cells were added in each well with the corresponding culture medium (completed 
up to 2 mL of medium per well). Once they reached 80 % confluency, cells were washed with 1X phosphate-
buffered saline (PBS) and fixed with cold 100 % methanol for 15 minutes at -20 °C followed by cold 100 
% acetone for 2 minutes at -20 °C. Fixed cells were washed for three times with 1X PBS at room temperature 
(RT), and kept in 1X PBS at 4 °C until used for staining. 
After fixation, cells were permeabilized with 1 % Triton X-100 / 1X PBS at RT for 5 minutes. Then 
coverslips were incubated with blocking solution (0,1 % Triton X-100 / 1 % bovine serum albumin (BSA) 
/ 1X PBS) at RT for 1h in a wet chamber. After aspiration of blocking solution, primary antibody was 
incubated for 2h at RT and then rinsed with 1X PBS at RT for 3 minutes, three times. Then, secondary 
antibody was added at a 1:600 dilution at RT for 45 minutes and then washed with 1X PBS for 3 minutes, 
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three times. Finally, a drop of mounting medium with DAPI (Thermo Fisher #P36962) was placed on top 
of the coverslip and it was mounted on a slide. Primary antibodies are summarized in Table 8.2 
(supplementary data). For secondary antibodies, anti-rabbit Alexa 594 (Thermo Fisher #Z25307) and anti-
mouse Alexa 594 (Thermo Fisher #Z25007) were used. Slides were put in the dark at -20°C for 20 minutes 
and then pictures were taken in the Zeiss AxioImager M2, in the Champalimaud Advanced BioImaging and 
BioOptics Experimental Platform at the Champalimaud Foundation, with 20x amplification. The 
quantification of the immunofluorescence was measured with a score that related the percentage area of red 
signal obtained by ImageJ® and the number of nucleus calculated with a semi-automatic software, QuPath. 
 
3.4 Western Blot 
3.4.1 Protein Extraction and Quantification 
Western blot (WB) is a technique that allows protein quantification and the first step was protein 
extraction, where Lysis buffer (RIPA buffer, Thermo Fisher #89900) was used, with anti-protease and anti-
phosphorylase reagents (Thermo Fisher #A32961), to avoid protein degradation and dephosphorylation. 
Lysis buffer was mixed with cell pellets and placed on ice (4 °C) for 30 minutes, being vortexed every 10 
minutes. Afterwards, solutions were centrifuged at 14000 rpm for 10 minutes at 4°C and the supernatant 
was recovered and quantified. Protein solution was stored at -80 °C for further immunoblot procedures. 
Bradford Law was the baseline to measure protein concentration using the Biorad Solution Protein 
Assay (Biorad #500-0006), following the manufacturer’s instructions. The standard curve was performed 
with BSA solution at different concentrations, in duplicates. dH2O was used as a blank. Before measuring 
the absorbance of the protein solution, 800 µL of dH2O, 1 µL of the sample and 200 µL of Biorad Solution 
were put inside of the spectrometry’s cuvette, in this particular order. After mixing the solution, it was 
incubated in the dark at RT for 5 minutes, and finally, the protein solution was read at 595 nm in the 
Ultrospec 2100 pro (Amersham Bioscience). 
3.4.2 Protein Running and Transference 
We used 50 µg of protein were used in a total volume of 30 µL for each blot. 4X Laemni dye (Bio-
Rad #161-0747) was added to the protein extract. The volume calculations are summarized in Table 8.3 
(supplementary data). Samples were boiled at 95°C for 5 minutes and later kept on ice until gel loading. 
The running box was prepared with 4-20% Mini-Protean® TGX™ Gels (Bio-Rad #456-1093) and running 
buffer (Tris-Glycine SDS (TGS) buffer) (Fisher Bioreagents #BP13414). Then, gel was loaded with 5 µL 
Prestained Rec Protein Ladder (Fisher Bioreagents #161-0374) and 20 µL of each sample. The run was 
performed at 80-100 V until the dye of the last ladder was at the very bottom of the gel.  
For transference of proteins to the membrane, semi-dry transfer technology was used. Foremost, the 
membrane and two pieces of filter paper in transfer buffer were cut and soaked in a solution, which includes 
5,82 g/L of Tris Base (Fisher Bioreagents #BP152-500), 2,93 g/L of Glycine (Fisher Bioreagents #BP381-
500), 0,375 g/L of SDS (Fisher Bioreagents #BP166-100), 200 mL of methanol (Acros Organics 
#423950010) and dH2O up to 1 L. To do the transfer, 1 wet filter paper was placed on the transfer equipment, 
and then the wet membrane on top, without bubbles. The gel was placed on top of the membrane, followed 
by the other wet filter paper and the machine was closed. The running was performed for 60-80 minutes 
with constant amperage (it was important that the voltage did not surpass 18 V). When the run stopped, the 
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Ponceau Red (Alfa Aesar #J63139) staining was used to check for visible bands in the membrane 
corresponding to the different molecular weight proteins. 
3.4.3 Immunoblotting 
Foremost, the membrane was blocked with 5% non-fat milk (5 g of milk (Bio-Rad #170-6404) in 100 
mL of 1X PBS on a rocker for 90 minutes at RT. Primary antibody was prepared in 5% non-fat milk solution 
and put on the membrane overnight at 4°C, in a rocker. The membrane was rinsed three times, for 30 
minutes, in 1X Tris-buffered saline (TBS, Thermo Scientific #28358). The secondary antibody was prepared 
in 5% non-fat milk solution and put on the membrane for 2 hours at RT. The membrane was washed three 
times for 30 minutes in 1X TBS. Developing solution Pierce ECL Plus Western (Thermo Fisher #32132) 
was prepared and placed on top of the membrane for 5 minutes, and imaged in the Amersham™ Imager 600 
machine (GE Healthcare Life Science). The same procedure with the loading control protein, β-actin, was 
performed in the original membrane to determine homogeneous protein load. However, to study S100A4 
protein expression, the membrane was blocked with a different blocking solution, BSA blocking solution 
(5 % BSA, 0,1 % Tween 20 and 1X TBS), instead of 5 % non-fat milk. The same BSA blocking solution 
was used for antibodies dilutions, although, the temperature and the time of incubation were the same as 
described before. Results were analyzed with ImageJ® and Adobe Illustrator. 
Primary antibodies used in this study are listed in Table 8.2 (supplementary data) and correspond to 
the same used for IF. A mouse anti-β-actin antibody (Sigma-Aldrich #MA1-91399) was used as the WB 
loading control. As secondary antibodies a goat anti-mouse IgG labeled with Horseradish Peroxidase (HRP) 
(Thermo Fisher #31432) and a mouse anti-rabbit labeled with HRP (Thermo Fisher #31464) were used.  
 
3.5 AGR2 Knock-Down Strategy  
3.5.1  TRC2-Lentiviral Plasmid Vector TRC2-pLKO-puro Features 
The vector used to knockdown AGR2 gene was the TRC2-Lentiviral Plasmid Vector TRC2-pLKO-
puro (Mission shRNA Bacterial Glycerol stock Sigma-Aldrich #SHCLNG) (Figure 3.2). This shuttle vector 
contains a bacterial ampicillin resistant gene as well as a puromycin resistance gene for mammalian cells. 
Generation of the lentiviral particles containing this plasmid was performed at the Molecular Biology 
Platform at the Champalimaud Foundation (Lisbon, PT).  
 
3.5.2 Plasmid Amplification 
In brief, 18µL of the bacterial stock were added to 500 µL of LB medium without antibiotics. The 
culture was incubated for 30 minutes by shaking at 37 °C. Then, using a sterile loop, 25 µL of the incubated 
culture were spread into a freshly prepared plate containing LB agar and carbenicillin for selection of the 
ampicillin resistant bacteria. The use of carbenicillin, an ampicillin analog, was favored over ampicillin due 
to its increased stability in cultures. The plate was incubated overnight in a humidified atmosphere at 37°C. 
One single colony was isolated and added to LB liquid medium. The plasmid DNA was extracted using 
EndoFree Plasmid Maxi Kit (Qiagen #12362) by following the manufacter’s protocol59. DNA integrity was 
verified by digestion with restriction enzymes HindIII, SacI and BamHI enzymes. The selection of the 
restriction enzymes was based on bioinformatics software (Snapgene) that, through plasmid sequence, 
detects which and where restriction enzymes hydrolyze the plasmid (Figure 3.2 B) and which one hydrolyze 
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shRNA sequence (Figure 3.2 A) and show the expected pattern of the restriction enzyme digestion gel 
(Figure 3.2 C). The experimental agarose gel corresponded with that of the one from the software (Figure 
3.2 D), meaning that the plasmid was validated and virus production could be initiated. 
 
3.5.3 Lentivirus Production 
The 293T cells were maintained with DMEM medium supplemented with 10 % FBS at 37°C in 
humidified atmosphere of 5 % CO2 in a 15 cm2 plate until reaching a confluency of approximately 90%. In 
the following day, the medium was replaced with 15 mL of OptiMEM and 10 % of FBS. Lipofectamine 
was prepared (2,5 mL of OptiMEM and 99,36 µL of Lipofectamine 2000 (Thermo Fisher #11668027) and 
Figure 3.2 TRC2-Lentiviral Plasmid Vector TRC2-pLKO-puro. A: shRNA sequence that is encoded between U6 promoter and 
cPPT of the plasmid and has a size of 58 base pairs (bp). AvaI, XhoI, PspXI, BsoBI and PaeR7I are the restriction enzymes that 
hydrolyze the shRNA sequence and, for that reason are not good enzymes to be used in performing the plasmid validation. B: 
TRC2-pLKO-puro is the plasmid that contains the shRNA sequence to knock down AGR2 gene and it has a size of 7484 bp. This 
plasmid includes U6 (U6 promoter), cPPT (Central polypurine tract), hPGK promoter (Human phosphoglycerate kinase eukaryotic 
promoter), puroR (Puromycin resistance gene for mammalian selection), WPRE (Woodchuck Hepatitis Post-Transcriptional 
Regulatory Element), 3’LTR (3’ self-inactivating long terminal repeat), SV40 poly (A) signal, SV40 ori, T7 promoter, M13 fwc, 
f1 ori (f1 orgin of replication), ampR promoter (Ampilicin resistance gene for bacterial selection), ori (origin of replication), CAP 
(Catabolite activator protein) binding site, lac promoter, lac operator, M13 rev, T3 promoter, RSV promoter, 5’ LTR (5’ long 
terminal repeat), RRE (Rev response element). SacI and BamHI are the restriction enzymes used to validate the plasmid, SacI 
enzyme cuts the plasmid in two similar fragments, approximately 3662 pb (green line), SacI plus BamHI enzymes hydrolyze the 
plasmid and form three different fragment: 3662 bp (green line), 1928 bp (blue line) and 1384 bp (red line). C: Expected agarose 
gel (1%) of the restriction enzymes digestion with the chosen enzymes given by the software. The fragment marked with a green 
circle corresponds to the fragment formed by SacI and SacI + BamHI hydrolyze (green line in B) and has a size of 3662 bp. The 
fragment marked with a blue circle corresponds to the fragment formed by SacI + BamHI hydrolize (blue line in B) and has a size 
of 1928 bp. The fragment marked with a red circle corresponds to the fragment formed by SacI + BamHI hydrolyze (red line in B) 
and has a size of 1384 bp. D: Agarose gel (1 %) of the restriction enzyme digestion of the amplified plasmid. The fragment marked 
with a green circle corresponds to the fragment formed by SacI and SacI + BamHI hydrolise (green line in B) and has a size of 3662 
bp. The fragment marked with a blue circle corresponds to the fragment formed by SacI + BamHI hydrolize (blue line in B) and 
has a size of 1928 bp. The fragment marked with a red circle corresponds to the fragment formed by SacI + BamHI hydrolise (red 
line in B) and has a size of 1384 bp. 
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then, it was incubated at RT for 5 minutes. DNA mixes were prepared according to the manufacter’s 
instructions, combined with lipofectamine and incubated at RT for 20 minutes. This mix was added to cells 
drop wise (5,1 mL per plate) and it was incubated at 37 °C. In the following day, the medium was removed, 
replaced with 15 mL of fresh DMEM medium with 10 % FBS and was incubated at 37°C, again. Viral 
supernatant was collected and spin-down at 3000 x g for 3 minutes, after one day. The supernatant was 
filtered with 0.45 µm filter cup. To concentrate the virus, LentiX Concentrator (Clontech #631231) was 
used and combined 3:1 of supernatant and lentiX, respectively. The mix was incubated at 4°C overnight. In 
the following day, virus concentration procedures were repeated and mixed with the first one, both having 
been centrifuged at 1500 x g for 45 minutes, followed by supernatant removal. Pellets were ressuspend in 
1/100 in 1X PBS and mixed. The aliquots were stored at -80 °C. 
 
3.5.4 Transfection of Cells 
A group of 100 000 cells of RT112_L_C and BFTC_L_C lines were grown and maintained on 6-well 
plates with medium as described in the section ‘3.1’. In the following day, the cells were infected. To 
transfect the cells, 10 µL of polybrene (10 mg/mL) (Thermo Fisher #TR-1003-G) were added to 10 mL of 
medium into a 15 mL sterile falcon tube. Then, 75 µL of the medium was added to 50 µL of the viral 
suspension into an eppendorf tube. In each well, 2 mL of medium with polybrene and 25 µL of viral mix 
were added. Plates were centrifuged at 600 rpm for 1 hour at RT. Afterwards, plates were incubated at 37 
°C in a humidified atmosphere of 5% CO2 overnight and, in the next day, the procedure was repeated. After 
two infections, 2 mL of fresh medium plus 2 µg/mL of puromycin (Gibco #A11138-02) were added to the 
cells in order to select those transfected. When cells were 90% confluent, the pellets were prepared to extract 
RNA and protein. During this process, fresh medium with puromycin was changed every two days. RNA 
was extracted and used to perform qRT-PCR as described in section ‘3.2’. The protein was extracted and 
used to produce WB as described in section ‘3.4’. Cells were plated in coverslips and IF performed as 
described in section ‘3.3’. 
 
3.6  Invasion Assays 
Invasion assay was performed using CytoSelect™ 24-well Cell Invasion Assay Kit (Cell Biolabs 
#CBA-110). The principle of invasion assay is to distinguish invasive cells from non-invasive cells. Invasive 
cells are able to degrade the matrix of proteins in the layer, and ultimately pass through the pores of the 
polycarbonate membrane, where they can be stained and quantified. On the day prior to the experiment, the 
medium of the cells was replaced with fresh medium without FBS (starvation). After rehydration of the 
basement membrane layer of the cell culture inserts, 180 000 cells of each cell line were transferred to a 
chamber and cells were growing with medium without FBS, however, outside of the chamber (inside of the 
well in a 24-well plate) there was medium supplemented with 10% of FBS.  
To accomplish the specific number of cells for each experiment we counted cells with a 
hematocymeter. After trypsinization, the cells were centrifuged at 1200 rpm for 3 minutes at 4 °C. The 
supernatant was removed and pellet was re-suspended with 4 mL of cold 1X PBS. All these procedures 
were performed at 4ºC. To obtain cell count of the suspension, 10µL of solution were mixed with 10 µL of 
Trypan Blue 0,2% (Gibco), with a 1:1 dilution. After mixing, 10µL of the mix was pipetted into the 
hemacytometer chamber and observed with an inverted microscope under a 10X objective with phase 
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contrast to distinguish viable cells (shiniest cells are the viable cells, blue-stained cells are non-viable). To 
calculate the number of viable cells (nVC) per mL of solution, the following formula (Equation 3.2) was 
applied: 
Equation 3.2: 
nVC x 104x L=
cells
mL
 
L=dilution 
 
The plate was incubated for 48 hours at 37 °C in 5% CO2 atmosphere. After 48 hours, the medium 
without FBS was removed, the inserts were stained with 400 µL of Cell Stain Solution and incubated for 10 
minutes at RT. After the inserts were washed, 200 µL of Extraction Solution were added to each well and 
the plate was incubated for 10 minutes at RT on an orbital shaker.  Each sample was transferred to a 96-
well plate and measured at 562 nm in a plate reader (BioTek #ELx800UV). For this procedure, 
manufacturer’s instructions were followed.  
 
3.7 Cell Proliferation assay 
Cell proliferation assay allowed studying the proliferative capacities of the cells and it was performed 
using CellTiter® 96 Aqueous Non-Radioactive Cell Proliferation Assay Kit (Promega #G5421). In order to 
measure the relative number of viable cells MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assays were done. The same number of cells 
(10 000 cells per well) were grown and maintained on 96-well plates. At 12, 24, 36, 48 and 72 hours, 20 µL 
of a 1:20 PMS/MTS solution were added to each well. The plate was incubated for 2 hours at 37 °C in a 
humidified and 5 % CO2 atmosphere. Absorbance was measured using a plate reader (BioTek #ELx800UV) 
at a wavelength of 490 nm. In every experiment, the absorbance of the MTS/PMS + medium solution 
without cells was always measured as a control. For this procedure, the manufacture’s introductions were 
followed. 
 
3.8 Cell Cycle Analyses 
Cell cycle analysis is a method to distinguish cells in different phases of the cell cycle through flow 
cytometry. One million cells were maintained as described in ‘3.1’. The cells were centrifuged at 1500 rpm 
for 5 minutes, ressuspended with 500 µL of 1X PBS and with 500 µL of cold 2 % PFA solution. Cells with 
PFA were incubated at 4°C for 1 hour. The suspension was centrifuged at 1500 rpm for 5 minutes and the 
pellet was ressuspended in 1X PBS. To fix the cells, 1 mL of cold 70 % ethanol was added drop wise doing 
vortex at the same time, to avoid cell agglomeration caused by ethanol. The cells were maintained in 70 % 
ethanol overnight at 4 °C. On the following day, cells were centrifuged at 1500 rpm for 5 minutes and 
washed with PBS for 10 minutes on ice to rehydrate. Centrifuge was repeated for 5 minutes at 1500 rpm 
and cells were ressuspended with 250 µL of PBS. 5 µL of 10 mg/mL of RNase A (Thermo Fisher #EN0531) 
were added to the suspension and incubated for 30-60 minutes at 37°C. The final procedure was to add 10 
µL of 1 mg/mL of propidium iodide (PI, Sigma #P4170-10MG) solution and solution was kept in the dark 
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at 4°C for at least 10 minutes or until analysis. Data was acquired on LSR Fortessa X20 cytometer with a 
blue laser (488 nm for GFP detection) and yellow-green laser (561 nm for PI detection). For each sample, 
at least 50 000 events were collected and data analysis was performed using ModFit LT™ version 4 with 
Watson Model for cell analysis after aggregate exclusion. Images were extracted from FlowJo® version 
10.3. 
The cell cycle analysis was performed with the help of the Flow Cytometry Platform of the 
Champalimaud Foundation (Lisbon, PT). 
 
3.9 In Vivo Bladder Orthotopic Model 
3.9.1 Inoculation of Bladder Cancer Cells 
To perform studies in vivo, 1x106 bladder tumor cells were inoculated in each Non-Obese 
Diabetic/Severe Combined Immuno Deficient (NOD/SCID) 5-7 weeks-old female mice. 5 mice for each 
cell line were used.  
Before given the injections, mice were first anesthetized in an induction chamber with 2-3% 
isoflurane and 0,5 mb O2, until not showing any reflexes. Mice were placed in supine position (on their 
back) on the face mask with 2-3% isoflurane on a warming path. 100 µL of cell solution containing the one 
million cells at RT were inoculated on the bladder of the female through the urethra, as previously described 
in the literature60, the catheter being kept inside the mice’s bladder for 30 minutes. The tail of the animals 
was marked with a permanent ink to distinguish them. The animals were checked and weighted every two 
days, to assess performance status. 4 weeks after the inoculation, in vivo imaging with the IVIS Spectrum 
system (Perkin-Elmer) was performed at the IMM (Lisbon, PT) to determine tumor progression as 
previously described. 
 
3.9.2 In Vivo Bioluminescent Imaging (BLI) 
Luciferin is a common bioluminescent reporter used for in vivo imaging of the expression of 
luciferase. Luciferase enzyme utilizes ATP and Mg2+ as co-factors to emit a characteristic yellow-green 
emission in the presence of oxygen, which shifts to red light in vivo at 37 °C. Experimental cell lines were 
originally transfected with the firefly luciferase gene (Figure 3.1) and intra-peritoneal injection of D-
luciferin (150 mg/kg of body weight, PromoKine #PK-CA707-10101-2), permitted the evaluation of tumor 
progression in vivo through BLI. For this procedure, the manufacturer’s instructions were followed.  
3.9.3 Histopathological Assessment 
After imaging, mice were sacrificed and all organs were fixed in 4% buffered formalin and processed. 
The sections were stained with Hematoxylin & Eosin (H&E) in the Histology and Comparative Pathology 
Laboratory of the IMM (Lisbon, PT). The slides with the sections were scanned in Pathology Platform of 
Champalimaud Foundation and images analyzed by Adobe Illustrator. 
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3.10 Statistical Analysis 
The statistical analysis was performed using SPSS® software version 24 (SPSS, Chicago, USA). The 
normality of the samples in the study was tested with Kolmogorov-Smirnov test. The comparison of means 
of qRT-PCR, WB, IF, cell cycle, proliferation and invasion assays results were tested with student t test 
when there were two sets, and ANOVA when were three categories. Whenever samples did not follow 
normality, non-parametric tests were used, such as Kruskal-Wallis when there were three sets of samples. 
A p-value < 0.05 (double-sided) was considered statistically significant. Except invasion assay, all 
experiments were performed in triplicate and repeated at least twice. Data are presented as mean ± standard 
deviation (SD) from 3 independent experiments. 
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4 Results 
 
Previously, work developed by our group showed that HG-NMIBC cell lines with loss of ∆Np63 
display higher proliferation rate in vitro and in vivo, higher invasion capacity in vitro and higher metastatic 
potential in an in vivo mouse model compared to cells with ∆Np63 expression (unpublished data). To 
validate these results, the orthotopic in vivo mouse assay was repeated in Lisbon with the RT112 cell line. 
1x106 cells were injected in the bladder of each female NOD/SCID mice and imaging in the IVIS was 
performed after 4 weeks. Consistent to previous findings, a higher tumor formation in the bladder was 
observed, as well as higher frequency in formation of metastasis formation in the kidneys in mice inoculated 
with ∆Np63 knock-down cells when compared to parental lines (∆Np63+) (Figure 4.1 A). Mice were 
sacrificed after imaging and their organs (bladder, heart, lungs, liver, kidney, spleen and thymus) were fixed 
in 4% buffered formalin and embedded in paraffin for histological evaluation (Figure 4.1 B). 
Figure 4.1 NMIBC cells with loss of ∆Np63 generate more tumors with a more aggressive phenotype. A: Mice inoculated with 
parental cells (left panel, ∆Np63+) developed less tumors in the bladder than mice inoculated with clone cells (right panel, ∆Np63-). 
(Images are from Mireia Castillo’s work in Dr. Cordon-Cardo’s Laboratory, Icahn School of Medicine at Mount Sinai, New York, 
USA). B: Histology analysis of the organs from NOD/SCID female mice four weeks after inoculation with RT112_L_P and 
RT112_L_C cells. Bladder tumor formation was higher in mice inoculated with RT112_L_C than with RT112_L_P, and kidney 
metastasis were only observed in mice inoculated with RT112_L_C. Scale bar: 50 µm. Organs were fixed in formalin, paraffin 
embedded and stained with H&E by the Histology and Comparative Pathology Laboratory of the IMM (Lisbon, PT).  
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Gene expression analyses previously performed by Dr.ª Mireia Castillo comparing parental lines and 
clones with ∆Np63 knock-down (BFTC and RT112) revealed that there were nine (AGR2, CAPS, CHD2, 
GCHFR, HOXC6, HRK, LRRC26, SORBS2 and S100A4) and four (EPDR1, PPARG, SCML1 and SPOCK1) 
commonly up-regulated and down-regulated genes, respectively, amongst the experimental cell lines. After 
literature review about their relevance in cancer, and search for primers and antibodies availability, four out 
of the nine up-regulated genes (AGR2, HOXC6, HRK and S100A4) and two out of the four down-regulated 
genes (SCML1 and SPOCK1) were chosen for further studies in this work. To validate gene expression 
analyses, mRNA expression was analyzed through quantitative real-time PCR. The difference of expression 
between the knock-down ∆Np63 cells (clones: BFTC_L_C and RT112_L_C) and the wild type cells 
(parental: BFTC_L_P and RT112_L_P) was compared, for each gene with GAPDH as internal control, in 
triplicate (Figure 4.2 A). These results showed that according to the RNA microarrays results, HRK mRNA 
showed a tendency of up-regulation in both bladder cancer cell lines whereas AGR2 mRNA showed 
statistically significant increased levels in BFTC_C and S100A4 mRNAs had a tendency of up-regulation 
in BFTC_L_C cells (blue) and down-regulation in RT112_L_C cells (red). On the contrary, HOXC6, 
SCML1 and SPOCK1 mRNAs showed a tendency of down-regulation in the ∆Np63 knock-down cells.  
Figure 4.2 mRNA and protein expression in BFTC_L_P, BFTC_L_C, RT112_L_P and RT112_L_C and control cell lines. 
A: mRNA expression of AGR2, HOXC6, S100A4, SCML1 and SPOCK1 through qRT-PCR. Comparison between cells with ∆Np63+ 
(P) and ∆Np63- (C). Data were normalized against GAPDH within the same sample. BFTC cells are represented in blue columns ± 
SD, n=3. RT112 cells are represented in red columns ± SD, n=3. Columns represent the mean from 3 separate experiments; each 
experiment was done in triplicates. *p-value < 0.05 by independent samples student t-test. B-B1: Western blot analysis of AGR2 
(20 kDa), HOXC6 (27 kDa), S100A4 (12 kDa) and SCML1 (37 kDa) protein level in BFTC_L_P, BFTC_L_C, RT112_L_P, 
RT112_L_C and in positive control tumor cell line. β-actin expression was the internal control. B2: Quantification of WB assay. 
Experiments were done in triplicates. Dark and light blue columns represent BFTC_L_P and BFTC_L_C, respectively. Dark and 
light orange columns represent RT112_L_P and RT112_L_C, respectively. Grey column represents the positive control. *p-value 
(AGR2 in BFTC) = 0,053 **p-value (AGR2 in RT112) = 0,068 by independent samples t-test. C: Quantification of 
immunofluorescence images taken from Zeiss AxioImager M2 microscope with 20x amplification (Figure 8.1) *p-value < 0,01 
**p-value < 0,05 by independent samples t-test. 
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In BFTC cell line, AGR2, HRK and S100A4 mRNAs showed tendency of up-regulation in clones 
comparatively to parental cells and SCML1 and SPOCK1 mRNAs showed propensity of down-regulation 
in the same situation, similar to gene expression analysis. HOXC6 mRNA had tendency of down-regulation 
in clones comparatively to parental cells in both NMIBC cell line which contradicts the results of gene 
expression analysis. In RT112 cell line, all of the tested mRNA (AGR2, HOXC6, S100A4, SCML1 and 
SPOCK1) showed tendency of down-regulation in clones cells, with only HRK mRNA showing propensity 
of up-regulation in clone cells. AGR2 mRNA overexpression in BFTC cell line was statistically significance. 
These results did not completely validate gene expression analysis and, for that reason, IF and WB assay 
were performed. 
The study of protein expression was essential to validate the previous results and with this in mind, 
WB and IF assays were performed for the same genes (Figure 4.2 B-C and Figure 8.1). Optimization of 
the antibodies was performed using positive and negative controls before WB assays in our experimental 
cell lines, described in Table 8.2. WB results suggest that the AGR2 and HOXC6 protein expression are 
significantly higher in clones than in parental cells, in both of bladder cancer cell lines (Figure 4.2 B). The 
S100A4 protein level is higher in clones than in parental cells in BFTC, but it could not be confirmed in 
RT112 cells (Figure 4.2 B). SCML1 protein expression is higher in parental than in clones cells in BFTC 
cell line and the opposite occurs in RT112 cell lines (Figure 4.2 B). The SPOCK1 protein was excluded 
from the immunofluorescence assay and western blot assays, given the lack of good antibodies for this 
protein. The HRK was excluded to the western blot analysis because the anti-HRK antibody was not 
detecting any band of the pretended size. Protein expression and their subcellular location were studied 
through immunofluorescence staining (Figure 4.2 C and Figure 8.1). All the antibodies were optimized 
before in positive and negative controls, and the final dilutions used are described in Table 8.2. AGR2 
protein is expressed in endoplasmic reticulum, HOXC6 and S100A4 are expressed in cell cytoplasm (Figure 
8.1 A-C). SCML1 is expressed in the nucleus (Figure 8.1 D). AGR2 WB analyses were performed in 
triplicates, whereas all other tests were performed only once, with these results we can only observe a 
tendency of expression, and more experiments need to be done to test their statistical relevance. 
Table 4.1 Summary of gene expression analysis, qRT-PCR, WB and IF results. The positive symbol (blue) correspond to results 
where the mRNA or protein is more expressed in clones than in parental cells. The negative symbol (orange) correspond to results 
where the mRNA or protein is less expressed in clones than in parental cells. Green circles mean that the result is not observable. 
Grey boxes indicated that the analysis was not performed. AGR2, HOXC6, HRK and S100A4 has higher gene expression in clones 
than in parental cells, whereas the opposite happens with SCML1 and SPOCK1 genes. Through qRT-PCR assay, AGR2 mRNA is 
higher expressed in clones in BFTC but is lower expressed in clones in RT112, as well as S100A4. HRK is higher expressed in 
clones than in parental in both bladder cancer cell lines. HOXC6 mRNA is lower in clones than in parental cells in both cancer cell 
lines. SCML1 and SPOCK1 mRNA are lower in clones than in parental cells. WB results suggest that AGR2 protein is more 
expressed in clones than in parental cells, as well as HOXC6 and S100A4 genes. SCML1 protein is lower expressed in clones than 
in parental, in BFTC cell line and the opposite in RT112 cell line. IF results suggest that AGR2 is more expressed in BFTC clones 
than in parental and lower in RT112 clones than in parental, whereas HOXC6 and S100A4 are more expressed in clones than in 
parental cells, in both of bladder cancer cell lines. 
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Through IF results, we observe a tendency of  AGR2 protein expression showing higher intensity in 
clones than in parental cells, in BFTC cell line and the opposite in RT112 cell line (Figure 4.2 C and Figure 
8.1 A). HOXC6 protein expression showed a tendency of higher expressed in clones than in parental, in 
both bladder cancer cell lines (Figure 4.2 C and Figure 8.1 B) as well as S100A4 protein expression (Figure 
4.2 C and Figure 8.1 C). SCML1 protein expression is lower in clones than in parental cells in BFTC cell 
line and the contrary tendency is observed in RT112 cell line (Figure 4.2 C and Figure 8.1 D). The up-
regulation of S100A4, in RT112_C, and SCML1, in BFTC_C was statistically significant. 
After reviewing all the obtained results from the mRNA and the protein expression analyses of AGR2, 
HOXC6, HRK, S100A4, SCML1 and SPOCK1, summarized in Table 4.1, we centered our future 
experiments to analyze AGR2 function in bladder cancer tumor progression. To test our hypothesis, AGR2 
gene was knock-down in BFTC_L_C cells, which had previously been ∆Np63 knocked down. After shRNA 
stable knock-down of AGR2, total RNA and protein were extracted and levels of AGR2 mRNA and protein 
were tested by qRT-PCR, WB and IF assays (Figure 4.3). 
Figure 4.3 mRNA and Protein expression in AGR2 knock down BFTC cell lines (clones A1, A2, A3, A4 and A5). 
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The qRT-PCR results showed that BFTC_A1, BFTC_A2, BFTC_A3 and BFTC_A5 present lower 
levels of AGR2 compared with BFTC_C, which after knockdown for ∆Np63 showed increased levels of 
this gene in comparison with BFTC_P cells. However, BFTC_A3 and BFTC_A5 were the cells with higher 
knockdown efficiency and consequently the ones with the lowest level of AGR2 mRNA expression. 
Notably, BFTC_A4 showed no decrease of AGR2 expression (Figure 4.3 A). The WB results validated the 
qRT-PCR results. Except BFTC_A4, all of the cells knocked down for AGR2 showed lower levels of this 
protein and those with the lowest level were BFTC_A3 and BFTC_A5 (Figure 4.3 B1-B2). The IF results 
were performed only in BFTC_A2, BFTC_A3 and BFTC_A5 because they corresponded to the cell lines 
with the lowest level of AGR2 protein. BFTC_A5 was the cell line with lowest level expression of AGR2 
protein by IF (Figure 4.3 C1-C2). In conclusion, qRT-PCR, WB and IF results identified BFTC_A5 as the 
clone with lowest level of AGR2 and for this reason that cell line was used to test the main hypothesis of 
this project: that without AGR2 protein, bladder NMIBC tumor cells would be less invasive, less 
proliferative and less aggressive. To study that, different in vitro experiments, such as cell cycle, 
proliferation and invasion assays were performed.  
 The cell cycle was analyzed by comparing the ratio between the number of cells in G2 and G1 
phases. The results showed that BFTC_C (∆Np63- AGR2+) had the highest G2/G1 ratio, followed by 
BFTC_A5 (∆Np63- AGR2-) and the lowest ratio in BFTC_P (∆Np63+ AGR2+). This means that after 
knocking down AGR2 in previously ∆Np63 knocked down cells, these cells have lower cell division, 
although not reaching the low levels of BFTC_P (∆Np63+ AGR2+) (Figure 4.4 A1-A2). The proliferation 
assay analyzes the activity of the cell and these results showed that BFTC_C (∆Np63- AGR2+) cells 
displayed higher proliferation rate than BFTC_P (∆Np63+ AGR2+) and BFTC_A5 (∆Np63- AGR2-) cells in 
vitro (Figure 4.4 B). Finally, BFTC_C (∆Np63- AGR2+) cells showed higher invasion capacity when 
compared with BFTC_P (∆Np63+ AGR2+) and BFTC_A5 (∆Np63- AGR2-) cells in vitro (Figure 4.4 C). 
Overall, BFTC_P (∆Np63+ AGR2+) showed lower cell division, lower cell proliferation and lower cell 
invasion in vitro, whereas BFTC_C (∆Np63- AGR2+) cells showed the highest cell division, the highest cell 
proliferation and the highest cell invasion in vitro. Moreover and in concordance with our hypothesis, 
BFTC_A5 (∆Np63- AGR2-) behaved in a similar way than BFTC_P (∆Np63+ AGR2+), going back to a less 
aggressive phenotype, results that suggest that AGR2 expression is important in tumor 
aggressiveness/progression. 
 
 
Figure 4.3 mRNA and Protein expression in AGR2 knock down BFTC cell lines (A1, A2, A3, A4 and A5). A: mRNA expression 
level of AGR2 gene through qRT-PCR. The expression of AGR2 gene was compared between the cells with ∆Np63+ phenotype 
(BFTC_P), ∆Np63- phenotype (BFTC_C) and ∆Np63- AGR2- phenotype (BFTC_A). All data were normalized against levels of 
GAPDH mRNA expression within the same sample. Columns represent the mean from three separate experiment and each 
experiment was done in triplicates. The results do not have statistical significance testes with independent t-test against BFTC_C. B-
B1: Quantification of western blot analysis of AGR2 (20 kDa) protein level in BFTC_A1, BFTC_A2, BFTC_A3, BFTC_A4, 
BFTC_45, BFTC_C and BFTC_P. BFTC_A2, BFTC_A3, BFTC_A5, BFTC_C and BFTC_P experiments were done in triplicates. 
*p-value < 0,05 by independent samples t-test against BFTC_C. B2: Representative western blot membrane of AGR2 protein. β-
actin protein expression was the internal control. C-C1: Quantification of immunofluorescence assay using anti-AGR2 antibody in 
BFTC_A2, BFTC_A3, BFTC_A5, BFTC_C and BFTC_P. *p-value < 0,05 by independent samples t-test against BFTC_C. C2: 
Representative immunofluorescence images taken from Zeiss AxioImager M2 microscope with 20x amplification. The grey column 
represents the cells knocked-down for ∆Np63 isoform and AGR2 gene ± SD, n=3, light blue column represents the BFTC_C cells ± 
SD, n=3 and dark blue column represents the BFTC_P ± SD, n=3. 
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Figure 4.4 Functional studies of BFTC_A5, BFTC_C and BFTC_P cell lines. A-A1: Representation of cell cycle results 
obtained by Flow Cytometry. The higher pick in 50K correspond to the G1 phase, while the pick in the 100K correspond to G2 
phase and between G1 and G2 phase is the S phase of the cell cycle. A2: Bar diagram of G2/G1 ratio of the cell cycle assay, n=2, 
in triplicates. Grey column represents the cells knocked-down for ∆Np63 isoform and AGR2 gene (BFTC_A5) ± SD, light blue 
column represents the BFTC_C cells (∆Np63-) ± SD and dark blue column represent the BFTC_P (∆Np63+)  ± SD. *p-value = 
0,002 **p-value = 0,004 by independent samples ANOVA test. B: Proliferation assay of BFTC_A5, BFTC_C and BFTC_P. 
Absorbance at 490 nm of cells and MTS were measure in 5 points for 72 hours. Grey line represents the cells knocked-down for 
∆Np63 isoform and AGR2 gene (BFTC_A5) ± SD, n=3, light blue line represent the BFTC_C (∆Np63-) cells ± SD, n=3 and dark 
blue line represent the BFTC_P (∆Np63+) ± SD, n=3, in quadruplicates. No significant results were observed by independent 
samples ANOVA test. C: Bar diagram of invasion assay of BFTC_A5, BFTC_C and BFTC_P cell line measure at 562 nm, n=1, in 
quadruplicates. Grey column represents the cells knocked-down for ∆Np63 isoform and AGR2 gene (BFTC_A5) ± SD, light blue 
column represent the BFTC_C cells (∆Np63-) ± SD and dark blue column represent the BFTC_P (∆Np63+) ± SD. *p-value = 0,013 
by independent samples Kruskal Wallis test. 
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5 Discussion 
 
The main goal of this project was to discover the genetic alterations associated with this ∆Np63 loss, 
TP63 isoform, which confer the aggressive phenotype to tumor cells. In the previous results of our group, 
it was observed that tumors with loss of ∆Np63 (BFTC_L_C and RT112_L_C) had higher proliferation rate 
both in vitro and in vivo as well as increased colony formation activity (unpublished data). Furthermore, 
these cells displayed superior invasion capacity in vitro, which correlated with higher local tumor initiation 
and metastatic potential in an orthotopic in vivo mouse model. The role of ∆Np63 in cancer is not well 
known. Karni-Schmidt et al. described that ∆Np63 can be a protective factor and act like a tumor suppressor 
in NMIBC however, this p63 isoform seems to have the opposite function in MIBC, where it has  an 
oncogenic role61. This antagonist role could be a consequence of the expression of the different ∆Np63 
isoforms (α, β and ƴ). These isoforms are not well known because there are no specific antibodies for each 
of them and because of that we are only studying the role of total ∆Np63 and assuming that the isoforms 
have the same role. In this work, we only studied HG NMIBC and total ∆Np63.  
Gene expression analyses revealed that there were nine (AGR2, CAPS, CHD2, GCHFR, HOXC6, 
HRK, LRRC26, SORBS2 and S100A4) and four (EPDR1, PPARG, SCML1 and SPOCK1) commonly up-
regulated and down-regulated genes in clones than in parental, respectively, amongst the experimental cell 
lines. To access the previous known involvement of all these genes in cancer biology, an extensive literature 
review was performed. After this research has been done, CAPS, CHD2, GCHFR, LRRC26, SORBS2, 
PPARG and EPDR1 genes were excluded from this work because of the inability to construct specific 
primers, or due to the absence of good antibodies available or they did not have any evidence in tumor 
development. On the other hand, AGR2, HOXC6, HRK, S100A4, SCML1 and SPOCK genes seemed 
interesting in the field of cancer. 
To validate gene expression analyses, mRNA expression of the chosen genes was analyzed through 
quantitative real-time PCR. The results revealed that AGR2 is higher expressed in clones (∆Np63-) than in 
parental cells (∆Np63+), only in BFTC cell line, although, in RT112 cell line seems that AGR2 is more 
expressed in parental cells (∆Np63+), however the difference is small. This result suggests that, in BFTC 
cell line, AGR2 is up-regulated when ∆Np63 is not expressed. The mRNA of HOXC6 is down-regulated in 
clones (∆Np63-) when compared with the parental cells (∆Np63+), in both BFTC and RT112 cell lines. The 
qRT-PCR result contradicts the gene expression analysis that had identified HOXC6 has an up-regulated 
gene in the same genetic background. The mRNA expression of HRK is higher in clones (∆Np63-) than in 
parental cells (∆Np63+), in both of the NMIBC cell lines. The mRNA of S100A4 is up-regulated in the clone 
cells (∆Np63-) when compared to the parental cells (∆Np63+) in BFTC cell line but not in the RT112 cell 
line. SCML1 and SPOCK1 mRNA levels are down-regulated in clone cells (∆Np63-). For the AGR2, HOXC6 
and S100A4 mRNA, RT112 cell line showed to express lower levels of all of the mRNA when ∆Np63 is 
not expressed (clones), which contradicts the gene expression results. SCML1 and SPOCK1 mRNAs 
exhibited lower levels and HRK mRNA exhibited higher level in clones (∆Np63-) than in parental (∆Np63+), 
in both NMIBC cell lines, which correlates with gene expression analysis. BFTC cell line exhibited higher 
levels of AGR2, HRK and S100A4 mRNA and lower levels of HOXC6, SCML1 and SPOCK1 mRNA, when 
∆Np63 is not expressed. All mRNAs studied by qRT-PCR, except AGR2 in BFTC cell line, did not show 
any statistical significance so the qRT-PCR results showed only a tendency of the mRNA expression.  
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The qRT-PCR results were not enough to validate the gene expression analysis because in some cases 
the results were not consistent with the gene expression microarray. Morey et al. reported that microarrays 
and qPCR data often result in disagreement and refer some factors that can contribute to that, such as the 
biological variability, the quality of RNA, the fold change and other factors. The biological variability 
cannot be controlled but it has to be considered. The quality of RNA is essential to obtain results, it can be 
affected by carry-over of contaminating factors and salts, alcohols, phenol, and other contaminating factors, 
which can affect reverse transcriptase used in qRT-PCR62. Moreover, gene expression is analyzed by 
informatics software and sometimes the results from this technique are not reproducible in vitro.  
Differences of results were not only observed between different techniques, but also between different 
NMIBC cell lines by the same technique. BFTC and RT112 cell lines are human high risk non-muscle 
invasive bladder cancer cells, tumors with elevate risk for progression to MIBC, developed several decades 
ago from women. Notably, they both show a mutation in TP53 gene. TP53 encodes the TP53 protein that is 
located in the nucleus of the cells and attached to the DNA, this protein has a role in damaged DNA repair 
and apoptosis, leading to preventing the tumor formation. Mutations in the TP53 tumor suppressor are the 
most frequent genetic alterations in cancer, these mutations have been associated with tumor progression 
and poor patient survival63–65. In bladder tumor, TP53 protein has also been reported as tumor progression 
factor66–68. The aim of this project was to study the NMIBC progression and to test whether an isoform of 
TP63, ∆Np63, was associated with this progression. For that reason, BFTC and RT112 were the chosen cell 
lines, both have TP53 mutation which is a factor of more aggressiveness phenotype and with this NMIBC 
cell lines was easier to verify if TP63 isoform was involved in tumor progression or not. However, the BFTC 
and RT112 cell lines showed different results when we performed qRT-PCR of the genes of interest was 
performed, which certainly could be consequence of a different genetic background. A study to compare 
the common mutations between BFTC and RT112 cell lines and a panel of the 409 genes most frequently 
altered in cancer was performed69 (Figure 8.2 (supplementary data)). BFTC cell line presented 447 
mutations but only 18 were common genes in the Ion Torrent panel, which are BAI3, BCL9, PKHD1, NRAS, 
BLM, TNK2, CDH11, PTCH1, ARID2, CDH20, TRRAP, SRC, IFGA9, FOXP1, SAMD9, DCC, CSFR1 and 
SOX2. We found that some of these genes were found to have a role in bladder tumor, such as ARID2 gene, 
which is considered a tumor suppressor that has function as chromatin remodeler, modulation of 
transcription and suppress cancer formation70. Moreover, SOX2 gene has been reported in bladder cancer 
specimens correlating with the presence of CIS and also the knockdown of SOX2 gene in bladder cancer 
cells has been described to attenuate tumor growth71,72. The RT112 cell line presented 298 mutations but 
only 10 were common with the genes of the Ion Torrent panel, which are KDM6A, EPHA7, NF1, MYC, 
PRDM1, FLCN, PIK3CA, HSP90AB1, CEBPA and HCAR1. The KDM6A gene encodes a protein that has 
histone demethylase function and has been found mutated in MIBC73. The MYC is a regulator gene and 
plays a role in cell cycle progression, apoptosis and cellular transformation74. The PIK3CA encodes a subunit 
of PI3K protein that controls cell growth, tumorigenesis, cell invasion and drug response. The PIK3CA gene 
alterations have been associated with reduced recurrence in NMIBC75. Some of these gene mutations could 
be molecularly connected with ∆Np63 isoform and/or with the genes that were studied and could lead to 
this distinct performance of the bladder cancer cell lines. BFTC and RT112 cell lines showed 22 common 
mutated genes, which are ESX1, NOS1, TENM4, APOB, ADAMTS2, AHNAK, TEMEM209, KIAA1551, 
KANSL1, NACA, MUC4, IBSP FAM83A, TRIM66, RYR2, ZNF853, MT-ND5, PRR12, KMT2C and 
PAPOLB, but only one was in common with the 409 important genes in tumor biology panel, the TP53 
gene, as referred above. 
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To validate the qRT-PCR results, protein studies were done to study the protein levels, and WB and 
IF assays were performed. WB is a good approach to protein quantification while IF is a good technique to 
verify the subcellular localization of the protein and allowing also its quantification, thus, they are 
complementary methodologies for protein expression assessment. WB results showed that AGR2 protein is 
more expressed in clone cells (both BFTC_L_C and RT112_L_C, ∆Np63-) than in parental cells 
(BFTC_L_P and RT112_L_P, ∆Np63+), which strongly suggests that when ∆Np63 is lost, AGR2 expression 
increase. The same result was observed for HOXC6 protein. The S100A4 protein showed higher level in 
clones (∆Np63-) than in parental (∆Np63+) cells but only in BFTC cell line, in RT112 no difference was 
observed by WB. The SCML1 protein was higher in parental (∆Np63+) than in clone cells (∆Np63-), only 
in BFTC cell line, whereas in RT112 the parental (∆Np63+) showed lower levels of this protein. These 
results suggest that when tumor cells have no expression of ∆Np63 isoform, AGR2, HOXC6 and S100A4 
proteins are up-regulated and SCML1 protein is down-regulated. HRK protein was also measured by WB, 
however given that a band with a molecular weight different to what was supposed to be observed, it was 
concluded that the anti-HRK antibody was detecting another protein and, for that reason, this analyses 
through IF was discontinued. All proteins studied by WB, except AGR2, were performed only once so, with 
these results, we can only observe a tendency and more experiments need to be done to test their statistical 
relevance. IF results showed the subcellular location of the proteins and the difference in expression level 
between parental and clones cells. AGR2 protein is expressed in endoplasmic reticulum and appears to be 
more expressed in clones (∆Np63-) than in parental (∆Np63+), in BFTC cell line, and the opposite in RT112 
cell line. HOXC6 and S100A4 proteins are expressed in the cell cytoplasm and this protein present higher 
level in clones (∆Np63-) than in parental (∆Np63+) cells, in both NMIBC cell lines. SCML1 is expressed in 
the nucleus and seems to be that is more expressed in clones (∆Np63-) than in parental (∆Np63+), only in 
BFTC cell line. The increased S100A4 protein level in RT112_C and the increased SCML1 protein level in 
BFTC_C were statistically significant, while the rest of the proteins levels were not. 
Usually, when a mRNA is overexpressed so is the respective protein. However, sometimes mRNA 
expression is not consistent with protein expression. AGR2, for example, appears to have higher mRNA and 
protein expression in clones (∆Np63-) comparatively to parental (∆Np63+) cells, in BFTC cell line. On the 
contrary, in the RT112 cell line, AGR2 displays lower mRNA expression and higher protein expression in 
clones (∆Np63-) than in parental (∆Np63+) cells. Down-regulation of mRNA concomitant with up-
regulation of protein expression could be consequence of protein half-life increase due to stabilization of 
protein-protein interactions and due to the turnover of the protein could be disrupted, this means that the 
ratio between protein synthesis and protein degradation was disturbed. Another possible reason for this to 
occur could be that mRNA might be degraded by some unknown mechanism. Usually, mRNAs are 
protected from degradation in cytoplasm by the cap and the poly (A) tail at the 5’ and 3’ extremities, 
respectively. However, those mRNAs may suffer a modification by, for example, endonucleases or 
exonucleases that generate a more fragile region, which will lead to mRNA degradation76. 
Studying the mRNA and the protein expression of the six selected genes (AGR2, HOXC6, HRK, 
S100A4, SCML1 and SPOCK1), AGR2 appears to be the most relevant gene for NMIBC development. 
AGR2 is a member of the protein disulfide isomerase (PDI) family of endoplasmic reticulum-resident 
proteins with molecular weight of 20 kDa, where it functions as a molecular chaperone in protein folding. 
Moreover, AGR2 is usually in the endoplasmic reticulum, but this protein can also be found in the nucleus77. 
AGR2 may control different aspects of tumor biology, such as, cell cycle, differentiation, migration, invasion 
and metastasis. AGR2 was found as a pro-oncogenic protein that attenuate TP53 activity by suppressing 
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TP53 phosphorylation after DNA damage78. Prometastatic characteristics of AGR2 protein are demonstrated 
by its interactions with C4.4A and alpha-dystroglycan (DAG-1) – two proteins that play have a role in 
metastasis formation79,80. AGR2 is overexpressed in a wide variety of tumors formed in different tissues with 
diverse patterns of genetic alterations, including cancers of the breast81,82, prostate83, lung84 and 
colorectum85. Moreover, AGR2 also supports aggressive growth and metastasis of a variety of cancer cells86–
88. A meta-analysis by Tian et al reported that AGR2 overexpression in breast cancer patients was 
significantly associated with poor survival89. Currently, very few studies have centered on AGR2 protein in 
bladder cancer. Interestingly, Melissa et al. recently described that bladder cancer cells secrete AGR2 while 
normal bladder cells express AGR2 but do not secrete it90. Furthermore, a humanized monoclonal antibody 
targeting secreted AGR2 has already been designed, which makes AGR2 an even more interesting gene to 
study as a tumor progression/predictive biomarker for patients with NMIBC91,92. 
To test the hypothesis that AGR2 may be involved in BC progression and aggressiveness, AGR2 gene 
was knocked down in BFTC clone cells, which had already suffered a knock-down of the ∆Np63. The 
knockdown of AGR2 was performed in both NMIBC, however RT112 cell lines took longer time to grow 
and it was impossible to perform the experiments in time to present this work. The knock-down of AGR2 
was performed in five different clones and RNA and protein were extracted from each to evaluate which 
had the lowest level of AGR2 mRNA and protein, tested also by qRT-PCR, WB and IF assays. The 
BFTC_A5 was the cell line that showed lower level of AGR2 mRNA and protein and, because of that, it 
was used to perform all the functional studies, such as cell cycle, invasion and proliferation assays. Cell 
cycle assay allowed to analyze the capacity for cell growth by quantifying the amount of DNA inside of a 
cell. Cell cycle was divided in G1, S, G2 and M phase, in this particularly order. In S phase, the DNA is 
duplicated and the division of the cell only happened in M phase. DNA was stained with propidium iodide 
in order to distinguish G2 and G1 phases because, given that if determined cells are dividing faster than 
others, they should have more number of cells in G2 phase in comparison to G1 phase. BFTC_C showed 
higher cell growth ratio than BFTC_A5 and BFTC_P which means that when bladder cancer cells do not 
express ∆Np63 they grow more. Notably, when we knock down AGR2 gene in these cells, their cell growth 
decreases. Thus, this methodology allowed confirming the important role of AGR2 in the control of tumor 
growth in BFTC cells. To deepen the knowledge of the function of AGR2 in tumor aggressiveness, 
proliferation assays were performed, which allowed the quantification of viable cells and to study their 
capacity to proliferate. Viable cells have the ability to reduce MTS in formazan product, which is soluble in 
culture media. BFTC_C showed the highest proliferation ratio, followed by BFTC_A5 and BFTC_P cell 
lines, which suggests that bladder tumor cells that express AGR2 and no ∆Np63 progress more than the 
ones with low expression of AGR2 and ∆Np63 proteins. Since this study is focused on HG NMIBC which 
means that they are NMIBC cells with high risk of progression to MIBC, it was important to evaluate the 
ability of invasion of these knockdown AGR2 cell lines. Invasion assays showed that BFTC_C displayed a 
higher invasiveness phenotype followed by BFTC_A5 and BFTC_P. These results suggest that tumor cells 
with no expression of ∆Np63 have higher ability to invade, however when AGR2 is low, this capacity is 
lost and the invasiveness decreases.  
Overall, tumors with low or no expression of ∆Np63 isoform display higher growth rate and 
proliferation capacity in vitro. Moreover, the absence of this gene showed increase invasiveness ability of 
the tumor in vitro. Furthermore, in vivo experiments performed to confirm previous findings, revealed that 
those cells have higher bladder tumor development and higher metastatic formation. Tumors with low or no 
expression of ∆Np63 isoform and AGR2 gene simultaneously showed lower growth rate, lower proliferation 
26 
 
capacity and less invasiveness in vitro, comparatively to cells with AGR2 gene expression. All results 
considered, AGR2 gene overexpression may be involved in tumor progression and in an aggressive 
phenotype. However it is still not known how AGR2 regulates these features and how this gene interacts 
with other genes involved in the tumor cell biology.  
In accordance with these results, ∆Np63 may inhibit AGR2 gene by an unknown mechanism                         
and when ∆Np63 is loss, AGR2 protein is up-regulated and has the ability to control cell growth, 
proliferation and invasion capacities of the tumor. This may be a consequence of AGR2 interaction with 
other proteins, such as C4.4A and DAG1 proteins that have already been reported in metastasis 
formation80,93. AGR2 is a protein located in the endoplasmic reticulum, however this protein has been 
already described in the nucleus, where it can regulate TP53 and other transcription factors, such as REPTIN 
protein77,94. REPTIN protein has a role in DNA repair, replication and transcriptional regulation and is 
overexpressed in various types of cancer, including bladder cancer95. It is proposed that ∆Np63 is able to 
inhibit AGR2 functions and that is one of the reasons why tumors with high ∆Np63 expression do not tend 
to progress as much as tumors with no or low ∆Np63 expression. Moreover, SOX2 gene is able to promote 
AGR2 function, and since it is found mutated in BFTC cells, this may lead to a higher decrease of AGR2 in 
those cells. Furthermore, AGR2 can act as a TP53 inhibitor and can also induce cell growth, metastasis and 
cell migration, interacting with other proteins, such as REPTIN, DAG-1 and C4.4A, among others (Figure 
5.1). 
 
 
 
 
 
 
 
 
 
 
To the author’s knowledge, this is the first study that described ∆Np63, TP63 isoform, interaction 
with AGR2 gene in progression of NMIBC. In this study, bladder tumor cells with no expression of ∆Np63 
gene displayed higher proliferation rate whereas those cells with no expression of AGR2 gene 
simultaneously, showed lower proliferations rate. These in vitro results suggest that AGR2 may be involved 
in tumor progression, tumor growth and tumor invasion in bladder cancer, however these experiments must 
Figure 5.1 Schematic representation of the proposed biological mechanism of AGR2 regulators and the AGR2 
interactions/functions. ∆Np63, an isoform of TP63, is able to inhibit AGR2 as well TP53 genes. TAp63, another p63 isoform, has 
the antagonistic function of ∆Np63 because it can promote transcription of TP53 gene. SOX2 gene and Estrogen (ES) are able to 
promote AGR2 expression and this protein interacts with other proteins, such as, REPTIN, DAG-1 and C4.4A, among others. These 
interactions lead to tumor cell growth, metastasis and cell migration. 
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be repeated to achieve, at least, 3 replicates. The proliferation assay has some technical issues because the 
number of cells transferred to the 96-well plate was very small and turned it inaccurate. The number of cells 
is a limiting factor since the well of the 96-well plate is very small and the confluency of the cells should be 
avoided before the end of the assay. So, for the future, proliferation capacities could be performed with other 
technique, such as cell trace cell proliferation through flow cytometry. This technique consists in staining 
the DNA and through subsequent cell divisions, daughter cells receive approximately half of the fluorescent 
label of their parent cells, allowing the analysis of fluorescence intensities that lead to a determination of 
the number of generations. Therefore, the number of generations is related with the proliferative capacities 
of the cells. 
 To better understand the relevance of AGR2 gene in bladder cancer progression, in vivo studies will 
be performed. Moreover, to confirm the findings in another setting, the same studies performed for BFTC 
cell line will be done for RT112 cell line.  Henceforth, immunofluorescence of AGR2 expression in T1 
NMIBC human specimen in tissue microarrays (TMA) will be performed to validate the in vitro and in vivo 
results, and to test whether AGR2 is a prognostic biomarker in this clinical setting. TMAs are used in the 
pathology clinical setting to molecularly characterize tumors in a simple and cost-effective manner. TMA 
studies will allow correlating AGR2 expression level with patient’s conditions, such as, prognosis, risk of 
progression, metastasis, time of survival, etc. Also, mechanistic studies will be important to elucidate how 
AGR2 induces the aggressiveness phenotype to clarify our hypothesis displayed in Figure 5.1.  
Afterwards, if AGR2 is a good factor of NMIBC progression, patients whose tumors are characterized 
by high levels of AGR2 protein may be treated with a humanized monoclonal antibody and followed by 
observation, in case of benefiting from this novel treatment. The development of a clinical trial to test this 
new therapeutic approach, if positive, could render a great alternative for patients for whom only radical 
cystectomy is currently available. Overall, in this work, AGR2 is described as a potential factor for 
progression of NMIBC to MIBC. AGR2 gene is important in tumor development and it can be a biomarker 
to distinguish the tumors that should (or not) undergo to a more invasive treatment. For example, cystectomy 
may be beneficial for clinically high-risk patients with a high progression score, while continued 
surveillance, BCG instillations and/or anti-AGR2 treatment may be beneficial for clinically high-risk 
patients with low progression score. Patients with low clinical risk but high progression scores may be 
monitored as clinically high-risk patients52.  
 In the future, it would also be interesting to do the same type of analyses with the S100A4 gene given 
it also has showed higher gene level, higher mRNA level and higher protein level in clones (∆Np63-) than 
in parental (∆Np63+) cells in BFTC cell line, and it is a well-known gene involved in tumor progression, 
never previously studied in NMIBC. 
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6 Conclusion 
 
NMIBC is a heterogeneous disease that includes tumors with high risk and low risk of tumor 
progression. Nowadays, using clinic-pathological features alone it is difficult to differentiate amongst these 
tumors and sometimes the oncologic patients suffers an overtreatment, mainly because the clinicians do not 
have the adequate tools to identify the high risk tumor that needs this radical treatment. Accordingly, the 
discovery of progression biomarkers is essential to decrease the overtreatment and to increase the quality of 
life of each patient depending on the type of tumor developed.  
∆Np63, isoform of TP63 gene, has been studied as a protective factor of NMIBC progression because 
when this isoform is down-regulated tumors have higher risk of progression, higher invasive capacities and 
higher metastasis formation. The main goal of this work was to discover the genetic alterations associated 
with ∆Np63 isoform loss that confers the aggressiveness phenotype of tumor cells. Interestingly, when 
∆Np63 is down-regulated AGR2 gene is up-regulated and, in this report, the AGR2 gene was identified as a 
potential factor of progression of NMIBC. The functional analyses performed after knock down of AGR2 
confirmed the implication of AGR2 in tumor aggressiveness, given that cells with low expression of AGR2 
showed lower proliferation rate and invasive capacities, as well as lower cell division, in vitro. However, 
more studies are needed to validate this hypothesis, such as in vivo tumorigenesis and metastasis assays and 
immunofluorescence analyses of AGR2 protein in T1 NMIBC patient samples tissues microarrays (TMA) 
that will enable to transfer these findings to a new level of scientific evidence. 
This work is the first to address the interaction between AGR2 and ∆Np63 and its role in tumor 
progression, allowing a better understanding of the mechanisms of BC progression. These results could 
help, in the future, to distinguish the low risk from the high risk tumors and could help clinicians to 
determine how patients with HG NMIBC should be treated, depending on their tumor molecular 
characteristics. Moreover, the existence of a humanized antibody against AGR2 could open the opportunity 
of performing clinical trials to test this novel therapeutic method for high risk T1 NMIBC, allowing a more 
conservative approach, thus improving patients’ quality of life. 
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8 Supplementary Data 
 
Table 8.1 Sequences of the primers used to perform qRT-PCR. 
Gene Sequence Ref. 
GAPDH 
F 5'-CAGCCTCAAGATCATCAGCA-3' 
18932030 
R 5'-GTCTTCTGGGTGGCAGTGAT-3' 
∆NP63 
F 5'-TGCCCAGACTCAATTTAGTGAG-3' 
20600197 
R 5'-TCTGGATGGGGCATGTCTTTGC-3' 
CHD2 
F 5'-GAGAATGCAAGGCCCTGAAGC-3' 
10336022 
R 5'-CCAGAAACAGTAAGGAAAATTGCAC-3' 
HOXC6 
F 5'-ATGAATTCGCACAGTGGGGTC-3' 
10336022 
R 5'-GGTACCGCGAGTAGATCTGG-3' 
HRK 
F 5'-GGCGGAACTTGTAGGAACGC-3' 
10336022 
R 5'-TTTTCACCAACCTGTTGCTCGC-3' 
S100A4 
F 5'-TCTTGGTTTGATCCTGACTGC-3' 
10336022 
R 5'-GCCCGAGTACTTGTGGAAGG-3' 
AGR2 
F 5'-TTGGGGAAAGGAAGGTTCG-3' 
10336022 
R 5'-CTCCATGGCAACTCGGATTTC-3' 
EPDR1 
F 5'-GCTGATCCCCTGCAAGAGATTATTT-3' 
10336022 
R 5'-GGCTGTGTCAGGGTCATCTT-3' 
SCML1 
F 5'-CAGGCTCTGTCACTAAAATAGGAAC-3' 
10336022 
R 5'-GATCTCGCATGGAAACGTTGG-3' 
SPOCK1 
F 5'-GCTCAGATGGCCACTCCTAC-3' 
10336022 
R 5'-TCTGTGCAGGCACTCCTTTC-3' 
 
 
Table 8.2 Summary of the antibodies and its respective characteristics. 
Gene anti- Clone # Catalog Company 
Dilution Molecular 
Weight 
(kDa) 
WB IF 
AGR2 rabbit monoclonal ab76473 Abcam 1:2000 1:100 20 
HOXC6 mouse monoclonal sc-376330 
Santa Cruz 
Biotechnology 
1:500 1:50 27 
HRK rabbit polyclonal ab45419 Abcam - 1:100 10 
S100A4 rabbit monoclonal 13018 Cell Signaling 1:1000 1:50 12 
SCML1 mouse monoclonal sc-135622 
Santa Cruz 
Biotechnology 
1:200 1:50 37 
β-actin mouse monoclonal 
MA1-
91399 
Thermo Fisher Scientific 1:10000 - 42 
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Table 8.3 Summary of volume of protein and reagents to perform the protein running assay. 
Average Protein 
Concentration 
Supernatant volume 
(40-50 µg) 
RIPA buffer Laemnie dye (4X) Total Volume 
N µg/µL (40/N) = x µL 22,5 – x µL 7,5 µL 30 µL 
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Figure 8.1 Immunofluorescence of AGR2, HOXC6, S100A4 and SCML1 proteins in BFTC_C, BFTC_P, RT112_C, 
RTT12_P and control positive cell lines. 
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Figure 8.1 Immunofluorescence of AGR2, HOXC6, S100A4 and SCML1 proteins in BFTC_C, BFTC_P, RT112_C, 
RTT12_P and control positive cell lines. A: Representative immunofluorescence using anti-AGR2 antibody in BFTC_L_C, 
BFTC_L_P, RT112_L_C, RT112_L_P cells and HeLa cells as positive control. B: Representative immunofluorescence using anti-
HOXC6 antibody on BFTC_L_C, BFTC_L_P, RT112_L_C, RT112_L_P cells and MCF-7 cells as positive control. C: 
Representative immunofluorescence using anti-S100A4 antibody on BFTC_L_C, BFTC_L_P, RT112_L_C, RT112_L_P cells and 
HeLa cells as positive control. D: Representative immunofluorescence using anti-SCML1 antibody on BFTC_L_C, BFTC_L_P, 
RT112_L_C, RT112_L_P cells and MCF-7 cells as positive control.  
 
Figure 8.2 Venn diagram of BFTC and RT112 mutated genes and their relevance in tumor biology. A panel of mutated genes 
described in BFTC and RT112 cell lines were compared with a panel of important genes in tumor biology described by IonTorrent69. 
18 out of the 487 mutated genes of the BFTC were in common with 409 panel of the important genes and they are BAI3, BCL9, 
PKHD1, NRAS, BLM, TNK2, CDH11, PTCH1, ARID2, CDH20, TRRAP, SRC, ITGA9, FOXP1, SAMD9, DCC, CSF1R and SOX2 
genes. 10 out of the 330 mutated genes of RT112 cell line were in common with 409 panel of the important genes and they are 
KDM6A, EPHA7, NF1, MYC, PRDM1, FLCN, PI3KCA, HSP90AB1, CEBPA and HCAR1 genes. BFTC and RT112 cell lines 
showed 22 common mutated genes, ESX1, NOS1, TENM4, APOB, ADAMTS2, AHNAK, TEMEM209, KIAA1551, KANSL1, NACA, 
MUC4, IBSP FAM83A, TRIM66, RYR2, ZNF853, MT-ND5, PRR12, KMT2C and PAPOLB, but only one was in common with the 
panel of the important genes that are TP53 gene. 
 
